GlassScriptPhysician profile
Christopher J Mancuso
NPI 1255725529
$22,110.29
in general payments reported to CMS, 2019-2025
32 companies · $2,304 in 2025
The $2,304 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,281 · 2020: $3,084 · 2021: $3,863 · 2022: $4,645 · 2023: $1,505 · 2024: $2,427 · 2025: $2,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,925 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,925.27 |
| Education | $311.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,864.27 | 2019-2025 | |
| Leo Pharma INC. | $2,565.02 | 2019-2025 | Adbry |
| Ucb, INC. | $2,400.91 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $1,477.10 | 2019-2025 | Tremfya |
| Genzyme Corporation | $1,420.47 | 2019-2025 | |
| Amgen INC. | $1,400.17 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $1,208.00 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $1,131.32 | 2019-2025 | |
| Lilly USA, LLC | $1,118.56 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $785.70 | 2021-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $763.82 | 2019-2024 | Dupixent |
| Pfizer INC. | $598.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $472.55 | 2021-2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $439.67 | 2019-2021 | |
| Celgene Corporation | $419.20 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $412.52 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $395.30 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $358.81 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $175.81 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $152.42 | 2022-2023 | Vtama |
| Genentech USA, INC. | $101.25 | 2022 | |
| Allergan, INC. | $97.33 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.34 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $67.90 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.96 | 2022 | |
| Biofrontera INC. | $43.53 | 2021-2025 | Bf-Rhodoled, Rhodoled Xl, Ameluz |
| Organon LLC | $31.61 | 2025 | Vtama |
| Incyte Corporation | $29.85 | 2025 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $22.88 | 2020-2021 | |
| Smith+Nephew, INC. | $13.61 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mancuso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.